ZimVie (NASDAQ:ZIMV – Get Free Report) is set to release its earnings data after the market closes on Wednesday, October 30th. ZimVie has set its FY 2024 guidance at 0.550-0.700 EPS.Investors interested in registering for the company’s conference call can do so using this link.
ZimVie (NASDAQ:ZIMV – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.04). ZimVie had a positive return on equity of 2.21% and a negative net margin of 63.84%. The business had revenue of $116.81 million during the quarter. During the same period last year, the business earned $0.17 EPS.
ZimVie Stock Performance
Shares of NASDAQ:ZIMV opened at $14.31 on Wednesday. ZimVie has a 12-month low of $6.52 and a 12-month high of $22.40. The company’s 50 day moving average price is $16.37 and its two-hundred day moving average price is $16.97. The firm has a market cap of $394.53 million, a PE ratio of -1.08 and a beta of 2.12. The company has a quick ratio of 1.43, a current ratio of 1.94 and a debt-to-equity ratio of 0.62.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on ZimVie
Insider Buying and Selling at ZimVie
In related news, major shareholder Camber Capital Management Lp sold 525,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $17.71, for a total transaction of $9,297,750.00. Following the sale, the insider now owns 2,725,000 shares in the company, valued at approximately $48,259,750. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.01% of the company’s stock.
About ZimVie
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
See Also
- Five stocks we like better than ZimVie
- How to Invest in the Best Canadian Stocks
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- EV Stocks and How to Profit from Them
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Stock Average Calculator
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.